Auna Delivers Strong Commercial Momentum Across Regional Healthcare Platform
Auna has announced its second-quarter 2026 earnings results, showcasing sustained commercial momentum across its regional healthcare platform. The company reported a 9% increase in consolidated revenue, driven primarily by volume growth and an improved mix of higher complexity services across all three of its markets.
Consolidated adjusted EBITDA decreased 9% on an FX neutral basis, attributed to temporary margin pressures in Mexico and Colombia, as well as the impacts of accepted penalties related to billing matters, primarily in Peru. However, Auna's underlying performance remains robust, with strong demand across its platform.
In Mexico, where the recovery in volumes accelerated during the quarter, surgeries increased by 7% and oncology chemotherapies and radiotherapies surged by 20% compared to the first quarter of 2026. This growth was attributed to improved tier classifications secured with major insurers and the expansion of Auna's oncology offerings.
Auna's President, Suso Zamora, highlighted the company's progress in operational enhancements implemented last year, particularly in Mexico. "We continue to see strong demand across our platform," said Zamora. "Our second-quarter results demonstrate sustained commercial momentum, and we remain committed to delivering growth and sustainable value for all stakeholders."
Consolidated revenue growth was also seen in Peru, where revenue increased by 8%, primarily attributed to a higher average ticket and sustained membership expansion. Auna's business model continues to benefit from the growth of high complexity surgeries and increasing penetration of the B2B market.
Looking ahead, Auna remains confident in its ability to deliver strong commercial momentum across its regional healthcare platform. The company's progress in operational enhancements and strategic growth initiatives positions it well for future success.
